Events
Meet BOC Sciences at AAPS PharmSci 360 2026 — Booth #811
Oct. 25–28, 2026, New Orleans, LA
Register
  1. Home
  2. Products
  3. ADC Linker
  4. Fmoc-Cit-PAB-OH

Fmoc-Cit-PAB-OH

  Cat No.: BADC-02037   Purity: ≥95% 4.5  

Fmoc-Cit-PAB-OH is a peptide linker containing an Fmoc-protected amine and citrulline residue, used as a building block for antibody-drug conjugates (ADCs). the Fmoc group can be deprotected under basic conditions to obtain the free amine for further conjugations, and it serves as a precursor or intermediate in the synthesis of cathepsin B-cleavable ADC linkers.

Fmoc-Cit-PAB-OH

Structure of 870487-04-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C28H30N4O5
Molecular Weight
502.56
Storage
Store at -20 °C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
(9H-Fluoren-9-yl)methyl (S)-(1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)carbamate; (S)-2-(Fmoc-amino)-N-[4-(hydroxymethyl)phenyl]-5-ureidopentanamide; (9H-Fluoren-9-yl)methyl N-[(1S)-4-(carbamoylamino)-1-{[4-(hydroxymethyl)phenyl]carbamoyl}butyl]carbamate; (S)-(9H-Fluoren-9-yl)methyl [1-[[4-(hydroxymethyl)phenyl]amino]-1-oxo-5-ureidopentan-2-yl]carbamate; Fmoc-Cit-PABA; Carbamic acid, N-[(1S)-4-[(aminocarbonyl)amino]-1-[[[4-(hydroxymethyl)phenyl]amino]carbonyl]butyl]-, 9H-fluoren-9-ylmethyl ester; Nα-Fmoc-L-citrulline (4-Hydroxymethyl)phenylamide
IUPAC Name
9H-fluoren-9-ylmethyl N-[(2S)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]carbamate
SMILES
C1=CC=C2C(=C1)C(C3=CC=CC=C32)COC(=O)N[C@@H](CCCNC(=O)N)C(=O)NC4=CC=C(C=C4)CO
InChI
InChI=1S/C28H30N4O5/c29-27(35)30-15-5-10-25(26(34)31-19-13-11-18(16-33)12-14-19)32-28(36)37-17-24-22-8-3-1-6-20(22)21-7-2-4-9-23(21)24/h1-4,6-9,11-14,24-25,33H,5,10,15-17H2,(H,31,34)(H,32,36)(H3,29,30,35)/t25-/m0/s1
InChIKey
KBTCNJJDJZRXCX-VWLOTQADSA-N
Density
1.315±0.06 g/cm3
Appearance
White to orange to green powder crystals
Storage
Store at -20 °C
Boiling Point
813.4±65.0 °C at 760 mmHg

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate | MAL-Di-EG-OPFP | 3-azidopropanoate-N-hydroxysuccinimide ester | Maleimide-NH-PEG10-CH2CH2COONHS Ester | Fmoc-N-amido-PEG2-acetic acid | 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)ethoxy)propanoate | AcLys-PABC-VC-Aur0101 intermediate-1 | 2,5-dioxopyrrolidin-1-yl 3-(2-(2-(1,3-dioxoisoindolin-2-yloxy)ethoxy)ethoxy)propanoate | 2,5-dioxopyrrolidin-1-yl 4-formylbenzoate | bis(2,5-dioxopyrrolidin-1-yl) 4,4'-disulfanediyldibutanoate | Fmoc-Cit-PAB-OH
Send Inquiry
Verification code
Inquiry Basket
Loading Loading......
Go to checkout